SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (3767)2/7/1998 8:55:00 PM
From: ALL  Read Replies (1) of 6136
 
I would like to speculate as to the rate of detectible patients who switched from IND or RIT/SAQ to Viracept in Abstract 387 at the Chicago Conference. Keep im mind that 13 or 39 or 33% of the patients who were on dual PI therapy (which may imply that a previous single PI therapy failed them)switched to a less optimal therapy of only one PI. As such, one might expect to see a 26% rate on detectability. One apple should be compared to one apple .....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News